Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
Novartis’ bid to expand use of SMA gene therapy delayed after FDA trial requestAnalysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal Share XNovartis’ bid to expand use of SMA gene therapy delayed after FDA trial requesthttps://pharmaphorum.com/news/novartis-bid-to-expand-use-of-sma-gene-therapy-delayed-after-fda-trial-request/
Transformational value – preparing for a decade of radical changeThe pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for Share XTransformational value – preparing for a decade of radical changehttps://pharmaphorum.com/whitepapers/preparing-for-a-decade-of-radical-change-in-pharma-transformational-value/
AI could drive health systems in lower-income countries – reportHealth systems in lower-income countries could overtake those in richer countries with AI-enabled technologies, according to a report Share XAI could drive health systems in lower-income countries – reporthttps://pharmaphorum.com/news/ai-could-drive-health-systems-in-lower-income-countries-report/
Roche hits back at Novartis with new data for MS drug OcrevusRoche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Share XRoche hits back at Novartis with new data for MS drug Ocrevushttps://pharmaphorum.com/news/roche-hits-back-at-novartis-with-new-data-for-ms-drug-ocrevus/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
Novartis eyes filings for leukaemia drug asciminib after phase 3 winA first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid Share XNovartis eyes filings for leukaemia drug asciminib after phase 3 winhttps://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/
Blow for Novartis as PD-1 drug spartalizumab flunks trialNovartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed Share XBlow for Novartis as PD-1 drug spartalizumab flunks trialhttps://pharmaphorum.com/news/blow-for-novartis-as-pd-1-drug-spartalizumab-flunks-trial/
